Changes in Beneficial Ownership · 4
Pharvaris N.V.
PHVSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-17
- Issuer
- Pharvaris N.V.
- Issuer CIK
- 0001830487
- Trading symbol
- PHVS
Reporting owner 1
- Name
- Lu Peng
- Reporting owner CIK
- 0001972159
- Relationship
- Officer
- Officer title
- President
- Address
- 1 CRANBERRY HILL SUITE 400, LEXINGTON, MA, 02421
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-17 | M · Form 4 | 100,000 | A | 2.59 | 164,953 | D |
| Common Stock | 2026-09-17 | S · Form 4 | 100,000 | D | 35 | 64,953 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 2.59 | 2026-09-17 | M · Form 4 | 13,308 | D | 0 | [F1] | 2030-02-03 | Common Stock | 13,308 | 0 | D |
| Stock Option (Right to Buy) | 2.59 | 2026-09-17 | M · Form 4 | 86,692 | D | 0 | [F1] | 2030-03-03 | Common Stock | 86,692 | 45,308 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Marnus Nel, Attorney-in-Fact for Peng Lu
- Date
- 2026-09-21
Company context
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by VIKING GLOBAL INVESTORS LP regarding Pharvaris N.V.Nov 16, 2026
- SCHEDULE 13G - filed by WELLINGTON MANAGEMENT GROUP LLP regarding Pharvaris N.V.Nov 16, 2026
- SCHEDULE 13G/A - filed by GENERAL ATLANTIC, L.P. regarding Pharvaris N.V.Nov 13, 2026
- 6-K filingNov 12, 2026
- 144 filingSep 23, 2026